LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MeMed Highlights Pioneering Blood Test for Accurately Distinguishing Between Bacterial and Viral Infection

By LabMedica International staff writers
Posted on 26 Apr 2022
Print article
Image: MeMed BV blood test accurately distinguishes between bacterial and viral infection (Photo courtesy of MeMed)
Image: MeMed BV blood test accurately distinguishes between bacterial and viral infection (Photo courtesy of MeMed)

MeMed (Haifa, Israel) hosted an integrated symposium, oral presentation and poster spotlighting MeMed BV at the 32nd European Congress of Clinical Microbiology and Infectious Diseases Conference (ECCMID) in Lisbon, Portugal, April 23-26, 2022. Clinical key opinion leaders presented clinical use and performance data in scientific sessions, including an integrated symposium, oral abstract presentation and poster abstract on MeMed BV performance validation data.

MeMed BV is a pioneering blood test to help physicians with the seemingly simple clinical dilemma - does a patient have a bacterial or viral infection. The test harnesses the power of the body’s immune system and delivers results in just 15 minutes. MeMed BV measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. MeMed BV is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies. The clinical studies demonstrating the diagnostic performance of MeMed BV encompassed thousands of patients and are published in high impact medical journals.

Unlike most conventional solutions that seek to detect bacteria or viruses, MeMed BV is an advanced host response test that uses the human immune system as the disease sensor. This approach offers unique advantages far beyond speed and accuracy: (i) It can diagnose cases when the infection site is not readily accessible or is unknown (e.g., pneumonia or fever without source) because immune markers circulate throughout the body; (ii) It can prevent false alarms due to detection of bacteria or viruses that are mere bystanders and are not causing the disease; (iii) It is robust to rapidly evolving pathogens. The MeMed BV test runs on MeMed Key, a cutting edge, compact immunoassay platform that is accurate and easy to use, making it possible to conduct highly sensitive, rapid, multiplexed protein measurements that previously could only be done on expensive central lab equipment.

Related Links:
MeMed 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.